No products in the cart.
Pre-made Cilgavimab benchmark antibody ( Whole mAb, anti-SARS-CoV-2 Spike RBD therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-105
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Cilgavimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Cilgavimab is a monoclonal antibody against the surface spike protein of SARS-CoV-2 [1]. It was developed by AstraZeneca. This mAb blocks spike binding to ACE2 and prevents infection in animals.
| Products Name (INN Index) | Pre-Made Cilgavimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody |
|---|---|
| INN Name | Cilgavimab |
| Target | SARS-CoV-2 Spike RBD |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2020 |
| Year Recommended | NA |
| Companies | AstraZeneca |
| Conditions Approved | NA |
| Conditions Active | COVID-19 |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | SARS-CoV-2 Spike RBD |
| Package |
Previous slide
Next slide
